从去年起，一款由国药与原研药企赛诺根（Seragon）合资引进的口服衰老抑制剂瑞拓龄（Restorin）登 录国药官方电商平台国药大集、京东、天猫等境内电商平台。作为赛诺根、哈佛、梅奥联合研发的革命 性衰老干预产品，吸引众多消费者，特别是高净值人群的密切关注。 瑞拓龄单套按120粒为单位售卖，售价约2000元，按照官方建议每日4至6粒服用剂量计算，月度成本可 达2000-3000元。仅天猫单个电商平台，瑞拓龄的累计销量就已超过一万，体现出当下人们对于科学可 靠的健康延寿产品的迫切需求。 作为国药旗下唯一一款口服衰老干预产品，瑞拓龄的技术来源于赛诺根联合哈佛大学、梅奥诊所等世界 顶尖机构研发的衰老干预候选药SRN-901，并早已于2024年公布部分关键数据，实验动物剩余寿命破纪 录延长33.02%的实验结果引发各界的广泛关注。 21世纪以来，瑞拓龄的技术研发方哈佛大学、梅奥诊所在衰老干预领域取得一系列的技术突破，使得衰 老干预和长寿医学领域成为全球医药学界的研发热点。除专业机构外，以PayPal联合创始人Peter Thiel、OpenAI首席执行官Sam Altman为代表的硅谷商业巨鳄们也豪掷千金，共同推动 ...

Core Insights - Nanjing Pharmaceutical (600713) has signed a strategic investment agreement with Guangzhou Baiyunshan Pharmaceutical Group and Guangzhou Guangyao Phase II Fund, marking a significant collaboration in capital, distribution channels, and traditional Chinese medicine [1] - The agreement involves the transfer of 11.04% of shares from Alliance Healthcare Asia Pacific Limited (AHAPL) to the Guangyao Phase II Fund at a price of 5.18 yuan per share, totaling approximately 750 million yuan, which is a 6.15% premium over the closing price prior to the agreement [1] Group 1: Nanjing Pharmaceutical's Growth - Since AHAPL's investment in 2014, Nanjing Pharmaceutical has seen substantial growth, with revenue increasing from 18.7 billion yuan in 2013 to 53.7 billion yuan in 2024, nearly tripling [3] - The net profit attributable to shareholders rose from 39 million yuan to 570 million yuan, representing an increase of over 14 times [3] - The growth is attributed to the management's efforts and support from AHAPL in terms of international experience and resources [3] Group 2: Walgreens Boots Alliance's Strategic Shift - AHAPL is a wholly-owned subsidiary of Walgreens Boots Alliance (WBA), which ranks 52nd on the Fortune Global 500 list with annual sales exceeding 1 trillion yuan [2] - WBA has been focusing on retail and health services while divesting from wholesale operations, including the sale of Alliance Healthcare to a leading North American drug distributor [2] - The recent share transfer aligns with WBA's global strategy to concentrate on its core retail and healthcare business [3] Group 3: Future Prospects and Investments - WBA has established a QFLP fund in Guangzhou with an initial capital of 1 billion yuan, focusing on the health, elderly care, and medical industries, indicating ongoing investment in emerging health sectors [4] - The company maintains a broad presence in the Asia-Pacific retail pharmacy and consumer business, including partnerships in China [4] - WBA's leadership has expressed optimism about the long-term prospects of the health and wellness industry, highlighting opportunities in artificial intelligence and retail pharmacy [4]

据介绍，长寿门诊历时超过一年的准备时间，最终曜影医疗集结心血管、内分泌、神经内科、运动医 学、营养、睡眠医学、心理与全科、中医科等多学科团队，结合分子与蛋白质组学、生物标志物、先进 影像与数字化平台，整合全球最新的生活方式医学证据，把妙佑医疗国际基于深厚循证医学证据的长寿 医学理念和先进的慢病与抗衰管理模式全面引进中国。 8月20日上午消息，在医疗机构妙佑医疗国际的官方指导下，近日曜影医疗正式在上海开设长寿门诊。 曜影医疗创始人兼首席执行官、上海曜影医院院长、心血管内科主任史浩颖博士表示，"长寿不仅是活 得更长，更是健康地活得更长。如果要用一句话定义曜影医疗的长寿门诊，这是国际标准的医疗级长寿 医学方案。" 责任编辑：杨赐 ...